PL3448409T3 - Leczenie chorób wątroby, dróg żółciowych i trzustki defensynami - Google Patents

Leczenie chorób wątroby, dróg żółciowych i trzustki defensynami

Info

Publication number
PL3448409T3
PL3448409T3 PL17727094.9T PL17727094T PL3448409T3 PL 3448409 T3 PL3448409 T3 PL 3448409T3 PL 17727094 T PL17727094 T PL 17727094T PL 3448409 T3 PL3448409 T3 PL 3448409T3
Authority
PL
Poland
Prior art keywords
defensins
liver
treatment
biliary tract
pancreas diseases
Prior art date
Application number
PL17727094.9T
Other languages
English (en)
Inventor
Peter NORDKILD
Søren Kjærulff
Original Assignee
Defensin Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defensin Therapeutics Aps filed Critical Defensin Therapeutics Aps
Publication of PL3448409T3 publication Critical patent/PL3448409T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17727094.9T 2016-04-29 2017-04-28 Leczenie chorób wątroby, dróg żółciowych i trzustki defensynami PL3448409T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670276 2016-04-29
DKPA201670484 2016-07-01
PCT/DK2017/050132 WO2017186250A1 (en) 2016-04-29 2017-04-28 Treatment of liver, biliary tract and pancreatic disorders

Publications (1)

Publication Number Publication Date
PL3448409T3 true PL3448409T3 (pl) 2026-02-23

Family

ID=58992579

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17727094.9T PL3448409T3 (pl) 2016-04-29 2017-04-28 Leczenie chorób wątroby, dróg żółciowych i trzustki defensynami

Country Status (13)

Country Link
US (1) US12076368B2 (pl)
EP (1) EP3448409B1 (pl)
JP (1) JP2019514908A (pl)
KR (1) KR102465341B1 (pl)
CN (1) CN109414474B (pl)
AU (1) AU2017258242B2 (pl)
BR (1) BR112018071972A2 (pl)
CA (1) CA3022497A1 (pl)
ES (1) ES3057685T3 (pl)
PL (1) PL3448409T3 (pl)
RU (1) RU2740913C2 (pl)
SG (1) SG11201809086YA (pl)
WO (1) WO2017186250A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
MX2021008249A (es) * 2019-01-07 2021-10-13 Aesculus Bio Aps Fragmentos de defensina para su uso en tratamientos o profilaxis.
CN110279851A (zh) * 2019-07-05 2019-09-27 浙江大学 Defa4细胞因子在制备治疗肝功能衰竭药剂中的应用
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2487895A1 (en) 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007133373A2 (en) 2006-05-01 2007-11-22 England Robert L TNF-α VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-α
CA2655022A1 (en) 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
WO2008115390A2 (en) 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
CN101980725B (zh) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
AR072524A1 (es) 2008-07-18 2010-09-01 Novozymes As Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos
EP2320930A2 (en) * 2008-07-18 2011-05-18 Novozymes Adenium Biotech A/S Treatment of inflammatory bowel diseases with mammal beta defensins
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110311601A1 (en) 2010-06-22 2011-12-22 Michael Kleine Antimicrobial medical devices
DE102010040153A1 (de) 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
CN103906528A (zh) * 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
US9217021B2 (en) * 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
AU2013311777B2 (en) * 2012-09-07 2018-02-01 Sanofi Fusion proteins for treating a metabolic syndrome
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用
CN105504063B (zh) * 2015-10-19 2019-10-01 中国医学科学院医药生物技术研究所 一类防御素-白蛋白的抗肿瘤融合蛋白及其制备和应用
RU2738265C2 (ru) 2016-01-26 2020-12-11 Дефенсин Терапьютикс Апс Способы модуляции кишечной микробиоты
CN108026130B (zh) * 2016-07-30 2021-04-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN114075585A (zh) * 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种β-烟酰胺单核苷酸的制备方法
CN112795606B (zh) * 2021-04-14 2021-07-27 深圳瑞德林生物技术有限公司 一种β-烟酰胺单核苷酸的酶催化合成方法
CN114107160B (zh) * 2021-12-27 2025-04-25 浙江英沃迪生物科技有限公司 一种烟酰胺核糖激酶基因工程菌及其应用

Also Published As

Publication number Publication date
CA3022497A1 (en) 2017-11-02
SG11201809086YA (en) 2018-11-29
US20190192626A1 (en) 2019-06-27
CN109414474B (zh) 2024-07-02
RU2018141326A (ru) 2020-05-29
AU2017258242B2 (en) 2024-04-04
JP2019514908A (ja) 2019-06-06
CN109414474A (zh) 2019-03-01
EP3448409A1 (en) 2019-03-06
AU2017258242A1 (en) 2018-11-29
RU2740913C2 (ru) 2021-01-21
US12076368B2 (en) 2024-09-03
EP3448409C0 (en) 2025-12-03
ES3057685T3 (en) 2026-03-04
RU2018141326A3 (pl) 2020-08-06
EP3448409B1 (en) 2025-12-03
KR102465341B1 (ko) 2022-11-09
WO2017186250A1 (en) 2017-11-02
BR112018071972A2 (pt) 2019-02-26
KR20190003592A (ko) 2019-01-09

Similar Documents

Publication Publication Date Title
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
DK3641819T3 (da) Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
DK3326641T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
IL262472A (en) Dpp3 inhibitors for use in treating diseases related to necrosis
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL245183B (en) Methods of treating and preventing graft versus host disease
IL258997B (en) Honey-cannabinoid therapeutic composition
IL269158A (en) Compositions and methods for treating inflammatory diseases
EP3426244C0 (en) 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND THEIR USES
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
PL3512517T3 (pl) Stosowanie pridopidyny w leczeniu lęku i depresji
IL250173B (en) Actuation mechanism and associated methods
IL268693B (en) Compounds for the treatment of glycogen storage disorders
EA201891679A1 (ru) Лечение рака онколитическим вирусом в комбинации с ингибитором контрольных точек
EP3884939C0 (en) 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND THEIR USES
IL259486A (en) Agents for the treatment of diseases associated with undesired cell proliferation
PL3448409T3 (pl) Leczenie chorób wątroby, dróg żółciowych i trzustki defensynami
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste